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The protein tyrosine phosphatase 
PTPN22 negatively regulates 
presentation of immune complex 
derived antigens
Fiona Clarke1, Harriet A. Purvis1, Cristina Sanchez-Blanco1, Enrique Gutiérrez-Martinez1, 
Georgina H. Cornish1, Rose Zamoyska2, Pierre Guermonprez1 & Andrew P. Cope  1
A C1858T single nucleotide polymorphism within PTPN22 (which encodes PTPN22R620W) is associated 
with an enhanced susceptibility to multiple autoimmune diseases including type 1 diabetes and 
rheumatoid arthritis. Many of the associated autoimmune diseases have an autoantibody component 
to their pathology. Fc receptors (FcRs) recognise autoantibodies when they bind to autoantigens and 
form immune complexes. After immune complex binding and receptor crosslinking, FcRs signal via 
Src and Syk family kinases, leading to antigen uptake, presentation and cytokine secretion. Ptpn22 
encodes a protein tyrosine phosphatase that negatively regulates Src and Syk family kinases proximal 
to immunoreceptor signalling cascades. We therefore hypothesised that PTPN22 regulates immune 
complex stimulated FcR responses in dendritic cells (DCs). Bone marrow derived DCs (BMDCs) from 
wild type (WT) or Ptpn22−/− mice were pulsed with ovalbumin:anti-ovalbumin immune complexes 
(ova ICs). Co-culture with WT OT-II T cells revealed that ova IC pulsed Ptpn22−/− BMDCs have an 
enhanced capability to induce T cell proliferation. This was associated with an increased capability of 
Ptpn22−/− BMDCs to present immune complex derived antigens and to form ova IC dependent DC-T cell 
conjugates. These findings highlight PTPN22 as a regulator of FcR mediated responses and provide a 
link between the association of PTPN22R620W with autoantibody associated autoimmune diseases.
The C1858T single nucleotide polymorphism in the human protein tyrosine phosphatase non-receptor type 22 
(PTPN22) gene encodes an R620W missense mutation in PTPN22 and is associated with an increased suscep-
tibility to multiple autoimmune diseases including rheumatoid arthritis (RA)1–4, systemic lupus erythematosus 
(SLE)5,6 and type 1 diabetes (T1D)7–9. PTPN22 (also known as PEP in the mouse) was first described as a negative 
regulator of Src and Syk family kinases downstream of the T cell receptor (TCR). In keeping with this function, 
Ptpn22−/− mice were subsequently reported to display enhanced TCR signalling that results in expansion of 
CD4+ effector T cells10. PTPN22 also regulates signalling downstream of additional receptors in various cell 
subsets, including the B cell receptor11, the αLβ2 integrin LFA-112, Toll-like receptors (TLRs)13 and dectin-114. 
Furthermore, PTPN22 functions to alter Src and Syk family kinase independent signalling events by regulating 
TRAF ubiquitination15. The R620W mutation is located in the P1 domain of PTPN22, which causes diminshed 
binding to the inhibitory tyrosine kinase Csk16,17. How the expression of PTPN22R620W affects the functions of 
different immune cells is not straight forward. Both gain- and loss-of-phosphatase function effects have been 
observed when investigating different signalling pathways in different cell types11,17–20.
Autoantibodies have long been implicated in the aetiology of autoimmune diseases including RA, type 1 dia-
betes, Graves’ disease and SLE; diseases for which PTPN22R620W is also a susceptibility risk allele21. Autoantibodies 
bind to self-antigens forming immune complexes which are recognised by Fc receptors (FcRs), thus inducing FcR 
mediated antigen uptake and cell activation. FcRs are expressed on the surface of most innate immune cells and 
are members of the immunoglobulin superfamily of receptors. FcRs recognise the Fc region of immunoglobulins, 
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with FcγRs specifically recognising the Fc regions of IgGs. Mice express four cell surface FcγRs: FcγRI, IIb, III 
and IV. FcγRI, III and IV are activatory receptors, whereas FcγRIIb is inhibitory22. Most innate immune cells 
express both activatory and inhibitory FcγRs, allowing for the modulation of downstream signalling. Activatory 
FcγR crosslinking induces Src family kinase activation, which in turn phosphorylates two tyrosine residues in 
the immunoreceptor tyrosine-based activation motif (ITAM), located in the associated common γ chain. Syk is 
then recruited via its tandem SH2 domains to the phosphorylated tyrosines. This initiates downstream signalling 
involving ERK, p38 and JNK, activating a range of cellular processes including DC maturation and cytokine pro-
duction23. For the inhibitory receptor FcγRIIb, phosphatases such as SH2-domain-containing protein tyrosine 
phosphatase 1 (SHP1) and SH2-domain-containing inositol polyphosphate 5′ phosphatase (SHIP1) are recruited 
to the immunoreceptor tyrosine-based inhibition motif (ITIM), located in the cytoplasmic tail of the receptor. 
Co-ligation of an activatory FcγR with an inhibitory FcγR reduces activatory signalling by dephosphorylation of 
signalling intermediates. Therefore, the cellular response to FcR signalling is dependent on the balance between 
the positive and negative signals. The necessity for appropriate regulation of FcγR signalling is demonstrated by 
the presence of polymorphisms in human FCGR genes which are linked to autoimmune diseases such as SLE, RA 
and multiple sclerosis24. Furthermore, mice lacking expression of the activatory FcγRs are resistant to a variety 
of autoimmune disease models such as collagen-induced arthritis25, but are susceptible to infections including 
Mycobacterium tuberculosis26.
ITAM signalling downstream of FcγRs in BMDCs is required for optimal T cell responses. This was demon-
strated using NOTAM BMDCs, which are unable to signal through ITAMs, but have normal FcγR cell surface 
expression27. NOTAM BMDCs show normal ovalbumin:anti-ovalbumin immune complex (ova IC) binding, but 
reduced uptake and degradation. As a result, NOTAM BMDCs are unable to present ova IC derived antigens 
on MHCI and MHCII (despite being capable of stimulating T cells when pulsed with ova peptide or protein)28. 
ITAM signalling was also demonstrated to be important using DAP12 and FcRγ doubly deficient mice, where 
BMDCs pulsed with ova coated beads were unable to cause OT-II T cell proliferation29.
Given the link between PTPN22R620W and autoantibody associated autoimmune diseases, and the regulation 
of FcRs by Src and Syk family kinases, we set out to investigate if PTPN22 regulates FcγR dependent immune 
complex uptake and activation in DCs and whether this can alter T cell effector responses.
Results
Immune complex pulsed Ptpn22−/− BMDCs cause enhanced T cell proliferation. In view of its 
known substrates, we hypothesised that PTPN22 should negatively regulate FcγR dependent immune responses. 
To determine whether PTPN22 modulates the capability of DCs to present immune complex derived peptides 
and in turn activate T cells, we carried out in vitro co-culture assays. Wild type (WT) and Ptpn22−/− BMDCs 
were pulsed with ovalbumin (ova) and ova immune complexes (ICs) and co-cultured with ova specific WT CD4+ 
OT-II T cells. After 6 days, T cell proliferation was assessed by CellTrace Violet (CTV) dilution. We have previ-
ously shown that ova and ova323–339 peptide pulsed WT and Ptpn22−/− BMDCs induce comparable WT CD4+ 
OT-II T cell proliferation30. Firstly, we confirmed published data31 demonstrating that ova IC pulsed DCs are 
potent activators of T cells when compared to non-complexed ova antigen, as seen by enhanced T cell prolif-
eration in response to ova IC pulsed BMDCs (Fig. 1a, Supplementary Fig. S1). We next compared the capa-
bility of ova IC pulsed WT or Ptpn22−/− BMDCs to induce T cell proliferation. Interestingly, we observed that 
ova IC pulsed Ptpn22−/− BMDCs induced enhanced T cell proliferation in comparison to WT BMDCs (Fig. 1a, 
Supplementary Fig. S1). This was accompanied by an increase in total cell numbers in the co-culture wells on 
day 6 (Fig. 1b). Enhanced T cell proliferation induced by ova IC pulsed Ptpn22−/− BMDCs was not explained by 
differences in T cell viability (Supplementary Fig. S1). Although T cells co-cultured with ova IC pulsed BMDCs 
secreted enhanced levels of IFNγ, TNFα and IL-17 (Fig. 1c), no consistent Ptpn22 dependent changes in expres-
sion of these cytokines were observed (Fig. 1c,d).
We also measured T cell proliferation and cytokine expression following 1 and 3 days of co-culture, to try 
to understand at what time point BMDC expression of PTPN22 regulated T cell proliferation. After 1 day of 
co-culture, CD25 and CD69 expression was enhanced on T cells co-cultured with Ptpn22−/− BMDCs pulsed 
with ova ICs (Supplementary Fig. S1). This was also accompanied by augmented IL-2 secretion (Supplementary 
Fig. S1). Finally, the total number of T cells per well was calculated after 3 days of co-culture, and this was found 
to be highest when T cells were co-cultured with Ptpn22−/− BMDCs pulsed with ova ICs (Supplementary Fig. S1).
Together, these data demonstrate that PTPN22 negatively regulates the capability of BMDCs to mediate 
immune complex dependent T cell activation.
PTPN22 is dispensable for FcγR induced BMDC maturation. We next sought to understand 
how PTPN22 might regulate the capability of immune complex pulsed BMDCs to induce T cell proliferation. 
FcγR stimulation induces the maturation of BMDCs, enhancing the cell surface expression of MHCII and 
co-stimulatory molecules including CD80, CD86 and ICAM-1; molecules capable of modulating T cell activa-
tion32. We therefore compared the capability of WT and Ptpn22−/− BMDCs to express co-stimulatory molecules 
in response to ova ICs. WT and Ptpn22−/− BMDCs were cultured in the presence of ova ICs (or ova and anti-ova 
alone) for 24 hours, and upregulation of MHCII and co-stimulatory molecules were assessed. Ova IC stimulation 
caused a subtle increase in cell surface expression of CD80 and CD86 (Fig. 2a,b), and expression was similar 
between WT and Ptpn22−/− BMDCs. This is despite the fact that Syk is required for upregulation of CD40 and 
CD86 on BMDCs after FcγR crosslinking33. As an additional control, WT and Ptpn22−/− BMDCs were cultured 
in the presence of ova pre-incubated with rabbit IgG, and ova with heat aggregated rabbit IgG. Neither conditions 
induced a change in the expression of CD80, CD86 or CD54; once again, these were only upregulated on BMDCs 
cultured in the presence of ova ICs (Supplementary Fig. S2).
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Immune complex stimulation also induces the secretion of T cell polarising cytokines by BMDCs34,35. Indeed, 
we observed that while BMDCs pulsed with ova ICs secreted significantly more IL-6, TNFα and IL-12/23p40 
compared to BMDCs incubated with ova alone, both WT and Ptpn22−/− BMDCs secreted similar levels of these 
cytokines in response to 24 hours of immune complex stimulation (Supplementary Fig. S3). To further investigate 
a potential role of PTPN22 in regulating immune complex induced cytokine secretion by BMDCs, we also carried 
out time course experiments. Secretion of cytokines was measured after 3, 6, 16 and 24 hours of immune com-
plex stimulation. PTPN22 was found to be dispensable for cytokine secretion at all time points (Supplementary 
Fig. S3).
Ova ICs bind to all FcγRs on BMDCs, so we hypothesised that, instead, selective FcγR binding might uncover 
differences in cytokine secretion. Therefore, IgG1 immune complexes, which preferentially bind to FcγRIIb and 
Figure 1. Ptpn22−/− BMDCs enhance immune complex induced T cell proliferation. (a–d) WT or Ptpn22−/− 
BMDCs were pulsed overnight in the presence of ova or ova IC prior to co-culture with CTV labelled WT CD4+ 
OT-II T cells for 6 days. (a) Proportions of WT OT-II T cells in each generation of cell division after 6 days of 
co-culture with ova (left) and ova IC (right) pulsed WT (white) or Ptpn22−/− (black) BMDCs (gated on live, 
CD3+, CD4+ singlets). n = 10 ± s.d.; **p < 0.01, *p < 0.05 using a Wilcoxon matched-pairs signed ranks test. 
(b) The number of cells per well were counted using trypan blue after 6 days of co-culture with ova IC pulsed 
WT (white) or Ptpn22−/− (black) BMDCs. n = 6; *p < 0.05 using a paired t-test. (c) At day 6 of co-culture cell-
free supernatants were assessed for IFNγ (left), TNFα (middle) and IL-17 (right) by immunoassay. n = 3–10. 
(d) At day 6 T cells co-cultured with ova or ova IC pulsed WT (white) or Ptpn22−/−(black) BMDCs were 
restimulated for 6 hours with PMA and ionomycin in the presence of monensin and intracellular expression of 
IFNγ (left), TNFα (middle) and IL-17 (right) was determined in live, CD3+, CD4+ singlets by flow cytometry. 
n = 4–9. Connecting lines indicate WT or Ptpn22−/− BMDCs co-cultured with the same WT OT-II T cells. 
n.s. = not significant using a 2-way ANOVA.
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FcγRIII were tested, but these also resulted in similar IL-6 and TNFα secretion from WT and Ptpn22−/− BMDCs 
(Supplementary Fig. S3). Together these data indicate that augmented T cell proliferation induced by immune 
complex stimulated Ptpn22−/− BMDCs cannot be explained by alterations in BMDC maturation, including 
upregulation of co-stimulatory molecules and cytokine secretion.
Immune complex binding, internalisation and degradation occur independently of PTPN22. 
FcγRs are phagocytic receptors that mediate antigen uptake and delivery of antigen into degradation and MHC 
presentation pathways, that ultimately lead to T cell activation35. We therefore sought to assess if PTPN22 reg-
ulated IC induced T cell proliferation by modulating the capability of BMDCs to internalise and process anti-
gens. Firstly, we demonstrated that ova IC uptake was indeed FcγR dependent by blocking uptake of fluorescent 
ova ICs (ova-AF488 ICs) with antibodies against FcγRI, FcγRII/III and FcγRIV (Supplementary Fig. S4). We 
next replicated findings reported previously36,37 that FcγR mediated uptake of immune complexes is dependent 
on Src and Syk family kinases, known targets of PTPN22. Indeed, pre-incubation of WT BMDCs with small 
molecular inhibitors of Src and Syk family kinases resulted in a significant reduction in ova-AF488 IC uptake 
(Supplementary Fig. S4). Having confirmed the dependence of Src and Syk family kinases in mediating IC uptake 
we next assessed if PTPN22 regulated this process. Despite the requirement for Src and Syk family kinases in 
internalisation of immune complexes, we found that PTPN22 was dispensable for FcγR dependent binding and 
uptake of ova-AF488 ICs (Fig. 3a,b).
Following antigen uptake protein antigens are lysosomally degraded into peptides and loaded on to MHCII 
molecules to form peptide-MHCII complexes. Changes in antigen degradation have the potential to alter the 
concentration or rate at which antigen is available to be loaded on to MHCII molecules. PTPN22 is required for 
TRAF3 ubiquitination, ultimately leading to the production of type I interferons13, and FcγR ubiquitination has 
been shown to facilitate internalisation and degradation of immune complexes38. Therefore, we next explored the 
Figure 2. PTPN22 does not regulate immune complex induced maturation of BMDCs. (a,b) WT or Ptpn22−/− 
BMDCs were stimulated in the presence of ova, anti-ova or ova IC. After 24 hours, BMDCs were harvested 
and surface stained for CD80, CD86 and MHCII. (a) Representative flow cytometry plots showing cell surface 
expression of CD80, CD86 and MHCII on WT (top) and Ptpn22−/− (bottom) BMDCs after 24 hour stimulation 
with ova (red), anti-ova (blue), ova IC (black), or left unstimulated (grey). (b) Pooled data (geometric mean 
fluorescence intensity, GMFI, gated on live, CD11c+ singlets) are shown for WT (white) and Ptpn22−/− (black) 
BMDC CD80 (left), CD86 (middle) and MHCII (right) expression. n = 6–8 + s.d.; ***p < 0.005, **p < 0.01 
using a 2-way ANOVA with Tukey’s multiple comparisons test. All WT v Ptpn22−/− comparisons were non-
significant (n.s.). Bars on graphs only show comparisons of ova IC v unstim/ova/anti-ova for Ptpn22−/− BMDCs 
(for simplicity).
www.nature.com/scientificreports/
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Figure 3. PTPN22 is dispensable for FcγR dependent immune complex binding, uptake and processing. (a) 
WT (white) or Ptpn22−/− (black) BMDCs were incubated with ova-AF488 ICs for 1 hour on ice. Cell surface 
ova-AF488 IC binding was determined by flow cytometry, gating on live, CD11c+, anti-rabbit+ singlets. 
n = 3–5 + s.d. (b) Combined ova-AF488 IC internalisation by WT (white) and Ptpn22−/− (black) BMDCs was 
determined by flow cytometry, gating on live, CD11c+, anti-rabbit- singlets. n = 3–5 ± s.d. (c) Representative 
flow cytometry plots showing ova-AF594:anti-ova coated bead internalisation and ova degradation by WT 
BMDCs over 0–7 hours at 37 °C. (d) Proportion of beads internalised by WT (white) and Ptpn22−/− (black) 
BMDCs that have degraded ova-AF594 on them (gated on single, anti-rabbit- beads). n = 3 ± s.d. (technical 
repeats, representative of 8 independent experiments). (e) Ova-AF594 geometric mean fluorescence intensity 
(GMFI) of beads internalised by WT (white) and Ptpn22−/− (black) BMDCs (gated on single, anti-rabbit- 
beads). n = 3 ± s.d. (technical repeats, representative of 8 independent experiments).
www.nature.com/scientificreports/
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possibility that PTPN22 might regulate the capability of BMDCs to mediate antigen degradation. To address this, 
WT and Ptpn22−/− BMDCs were incubated with ova-AF594:anti-ova coated polystyrene beads. Over time the 
intensity of the ova-AF594 signal is lost, indicative of antigen degradation30. However, both the amount of degra-
dation and the proportion of beads with degraded ova were similar in antigen loaded WT and Ptpn22−/− BMDCs, 
indicating that ova-AF594:anti-ova degradation also occurs independently of PTPN22 (Fig. 3c–e). Collectively, 
these data demonstrate that PTPN22 is not required for FcγR dependent immune complex binding, uptake and 
degradation, showing that these processes are unlikely to be responsible for the Ptpn22 mediated differences 
observed in immune complex induced T cell proliferation.
PTPN22 negatively regulates immune complex derived antigen presentation and DC-T cell con-
jugate formation. As FcγR dependent immune complex binding, uptake and processing was found to occur 
normally in the absence of PTPN22, we set out to determine whether PTPN22 was required for loading of immune 
complex derived peptide antigens on to MHCII. WT and Ptpn22−/− BMDCs were incubated with GFP-Eα:anti-GFP 
immune complexes for 5 or 18 hours, and an antibody (YAe) specific for I-Ab restricted presentation of an Eα pep-
tide (Eα52–68) was used to determine cell surface presentation of immune complex derived antigens. After 5 hours 
of incubation, similar proportions of WT and Ptpn22−/− BMDCs expressed Eα52–68 peptide-MHCII complexes at 
the cell surface (Supplementary Fig. S5). However, when BMDCs were incubated with GFP-Eα:anti-GFP immune 
complexes for 18 hours (the point at which ova IC pulsed BMDCs are harvested for co-culture assays), although 
similar proportions of WT and Ptpn22−/− BMDCs expressed Eα52–68 peptide-MHCII complexes at the cell sur-
face (Fig. 4a, b), we observed that Ptpn22−/− BMDCs expressed higher levels of Eα52–68 peptide (as measured by 
increased geometric mean fluorescence intensity, GMFI, Fig. 4b). Furthermore, the increase in Eα52–68 peptide on 
the cell surface of Ptpn22−/− BMDCs was not due to differences in MHCII cell surface expression between WT and 
Ptpn22−/− BMDCs (Supplementary Fig. S5). Likewise, in agreement with our data showing no role of PTPN22 in IC 
uptake (Fig. 3b), uptake of the GFP-Eα:anti-GFP immune complexes was comparable in the presence or absence of 
PTPN22 (Supplementary Fig. S5). We conclude that enhanced expression of peptide-MHCII on immune complex 
pulsed Ptpn22−/− BMDCs could, at least in part, be responsible for the increased T cell proliferation observed in 
Fig. 1. The effect of PTPN22 on Eα52–68 peptide-MHCII complex expression was only observed at the later 18 hour 
time point, indicating that PTPN22 may regulate the rate of peptide-MHCII complex trafficking and/or retention at 
the cell surface, rather than initial complex formation.
We hypothesised that if Ptpn22−/− BMDCs were capable of enhanced peptide-MHCII presentation then this 
would result in enhanced formation of DC-T cell conjugates, which could potentially lead to greater T cell pro-
liferation. To test the requirement for PTPN22 in the formation of DC-T cell conjugates, WT and Ptpn22−/− 
BMDCs were pulsed overnight with ova or ova ICs, stained with CellTrace Far Red (CTFR) and incubated with 
CellTrace Violet (CTV) stained WT OT-II CD4+ T cells. We observed that unpulsed and ova pulsed BMDCs 
formed only low frequencies of CTV+ CTFR+ conjugates (Supplementary Fig. S6), whereas ova IC pulsed 
BMDCs formed more conjugates, which increased over time (Fig. 4c). Interestingly, in agreement with our 
hypothesis, we observed that ova IC pulsed Ptpn22−/− BMDCs had a significantly enhanced capability to form 
conjugates with WT OT-II T cells than WT BMDCs (Fig. 4c). PTPN22 does not regulate DC-T cell conjugate 
formation in all contexts, as we have previously found that conjugate formation of ova323–339 peptide pulsed, 
LPS matured WT and Ptpn22−/− BMDCs is similar30. Together the enhanced capability of Ptpn22−/− BMDCs to 
present immune complex derived antigens and form T cell conjugates, could explain the enhanced T cell prolifer-
ation induced by immune complex stimulated Ptpn22−/− BMDCs. How PTPN22 is regulating BMDC enhanced 
immune complex derived antigen presentation and conjugate formation is unclear. Nonetheless, we observed 
that immune complex induced DC-T cell conjugate formation was dependent on Src and Syk family kinases 
(Supplementary Fig. S6), indicating that PTPN22 may be regulating this process via its ability to dephosphorylate 
these kinases. Finally, we observed altered FcγR expression on the surface of Ptpn22−/− BMDCs prior to FcγR 
activation; specifically, reduced expression of the inhibitory FcγRIIb (Fig. 4d, Supplementary Fig. S7). Reduced 
expression of the inhibitory receptor may alter the activatory/inhibitory (A/I) ratio, thus potentially reducing 
the negative regulation downstream of activatory FcγRs. These data suggest that PTPN22 acts to regulate FcγR 
dependent immune responses, reducing the capability of DCs to activate T cells.
Discussion
Self-antigen immune complexes are a prominent feature of multiple autoimmune diseases including RA, T1D, 
Graves’ disease and SLE, diseases also associated with PTPN22R620W. FcRs mediate antigen:antibody immune 
complex internalisation and subsequent immune complexed antigen processing and presentation, leading to the 
activation of an adaptive T cell immune response. Here we aimed to investigate whether PTPN22 regulates FcγR 
dependent immune responses. We report that immune complex pulsed Ptpn22−/− BMDCs are more effective 
at promoting CD4+ T cell proliferation and that this is associated with both enhanced presentation of immune 
complex derived antigens at the cell surface and DC-T cell conjugate formation. Together, these data demonstrate 
for the first time that PTPN22 negatively regulates FcγR dependent T cell activation by BMDCs, and suggests that 
perturbations to PTPN22 regulates DC/T cell activation in response to immune complexes.
Previous investigations have reported conflicting results regarding the role of PTPN22 in FcγR independ-
ent internalisation and presentation of ovalbumin by BMDCs19,39. However, our own investigations indicate that 
PTPN22 is dispensable for non-specific antigen uptake and processing30. Here, our novel findings suggest that 
FcγR dependent uptake of ova ICs by Ptpn22−/− BMDCs results in enhanced T cell activation. Interestingly, we 
observed that rather than regulating the amount of ova IC internalisation, PTPN22 appears to specifically regulate 
MHCII restricted antigen presentation by BMDCs and DC-T cell conjugate formation. One explanation for this 
observation may lie in PTPN22 regulating FcγR dependent antigen compartmentalisation; whereby inflammatory 
signals promote loading of antigens on to MHCII40. In this context, the absence of PTPN22 may confer a subtle 
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Figure 4. Ptpn22−/− BMDCs present more immune complex derived antigens and form more conjugates with 
T cells. (a) Representative flow cytometry plots of Eα52–68 surface expression in I-Ab by WT (top) and Ptpn22−/− 
(bottom) BMDCs after 18 hour incubation with GFP:anti-GFP ICs (left) and GFP-Eα:anti-GFP ICs (right). 
(b) Combined proportion (left) and geometric mean fluorescence intensity (GMFI, right) of Eα52–68 surface 
expression in I-Ab by WT (white) and Ptpn22−/− (black) BMDCs after 18 hour incubation with GFP:anti-GFP 
ICs and GFP-Eα:anti-GFP ICs (gated on live, CD11c+ singlets). n = 3 + s.d.; *p < 0.05 using a 2-way ANOVA 
with Sidak’s multiple comparisons test. (c) Proportion of WT OT-II T cells in conjugates with ova IC pulsed 
WT (white) and Ptpn22−/− (black) BMDCs over time. Conjugates were identified as CTV+ CTFR+ events (%, 
gated on CTV+ total T cells). n = 4 ± s.d.; **p < 0.01 using a 2-way ANOVA with Sidak’s multiple comparisons 
test. (d) Cell surface FcγR expression on WT (white) and Ptpn22−/− (black) BMDCs (gated on live, CD11c+ 
singlets). n = 16 + s.d.; ***p < 0.005 using a 2-way ANOVA with Sidak’s multiple comparisons test.
www.nature.com/scientificreports/
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but functionally important enhancement in FcγR dependent inflammatory signals that target immune complexed 
antigen for MHCII presentation. This increase could potentially be due to PTPN22 mediated changes to the balance 
of inhibitory FcγRIIb and activatory FcγRIII expression on the DC surface (Fig. 4d). PTPN22 has also been demon-
strated to negatively regulate the phagocytic fungal pathogen receptor dectin-1, although PTPN22 was found to 
have no effect on dectin-1 dependent C. albicans phagocytosis14. However, data presented here suggest that PTPN22 
may regulate MHCII presentation of C. albicans antigens and subsequent C. albicans restricted T cell activation. 
Together, our data indicate a role for PTPN22 in regulating FcγR dependent MHCII loading, which has the potential 
to enhance immune complexed self-peptide presentation, increasing subsequent T cell activation.
The role of PTPN22 in the regulation of FcγR signalling has been previously addressed in the context of neu-
trophils, where PTPN22 is required for optimal immune complex induced ROS production, adhesion and degran-
ulation41. In contrast, we observed no differences in FcγR induced BMDC co-stimulatory molecule expression or 
cytokine secretion, but a more specific role of PTPN22 in the negative regulation of immune complexed antigen 
presentation by BMDCs. This indicates that the requirement for PTPN22 in the context of FcγR signalling may 
differ depending on the cell type. Neutrophils are also capable of mediating MHCII antigen presentation42, and so it 
would be interesting to assess if in neutrophils, where PTPN22 has been demonstrated to positively regulate multiple 
effector functions, FcγR mediated antigen presentation is positively or negatively regulated by PTPN22.
FcγRs internalise immune complexes via receptor mediated endocytosis, a process which utilises Src and 
Syk family kinases43. Syk is essential for FcγR mediated uptake in macrophages44, neutrophils44 and dendritic 
cells33, and Src family kinases are not essential but are required for optimal uptake of IgG opsonised particles by 
macrophages36. Our data confirmed that efficient internalisation of ova ICs requires Src and Syk family kinase 
signalling (Supplementary Fig. S4). Despite this, however, PTPN22 (which dephosphorylates Src and Syk family 
kinases) was found to be dispensable for ova IC uptake (Fig. 3b). One likely explanation for this is that regula-
tion of FcγR proximal kinase phosphorylation is mediated by phosphatases other than PTPN22. Tyrosine phos-
phatases including SHP-1 and SHP-2, in addition to inositol phosphatases SHIP-1 and SHIP-2 have each been 
demonstrated to regulate kinase signalling downstream of FcγRs. Another possibility is that PTPN22 exerts a 
subtle effect, fine tuning signals downstream of FcγRs, to specifically regulate MHCII antigen presentation, rather 
than broader BMDC effector functions. Our data does not allow us to distinguish if PTPN22 operates to control 
FcR dependent antigen presentation by regulating Eα52–68 peptide-MHCII formation, trafficking to the cell sur-
face, or presentation of these complexes on the cell surface. Dendritic cells use endolysosomal tubules to transport 
peptide-MHCII complexes to the cell surface, for presentation to T cells45. In a murine B cell line, Syk was shown 
to be required for efficient formation of peptide-MHCII complexes46, and ITAM signalling is required to main-
tain peptide-MHCII complexes on the surface of dendritic cells29. These data may indicate that in the absence of 
PTPN22 mediated dephosphorylation, Syk activity is enhanced leading to increased formation of peptide-MHCII 
complexes on the cell surface of immune complex pulsed Ptpn22−/− BMDCs.
Like PTPN22, fellow PTPN22 family member PTPN1247, is also dispensable for ova protein induced T cell 
proliferation, but is required for the induction of optimal IFNγ secretion by T cells48. These data indicate that 
members of the same phosphatase family can be redundant for antigen internalisation, yet act to regulate specific 
and independent DC effector functions. Indeed, since Ptpn22−/− BMDCs will express PTPN12, this may also 
explain why IFNγ secretion was similar by T cells co-cultured with ova IC pulsed WT and Ptpn22−/− BMDCs.
Since our data indicate that the absence of PTPN22 enhances FcγR dependent antigen presentation, it 
may have implications for individuals harbouring the PTPN22R620W polymorphism. PTPN22R620W affects the 
protein binding region of the P1 polyproline domain, and this mutation has been found to cause a gain- or 
loss-of-function depending on the cell type and signalling pathway being regulated. If PTPN22R620W acts as a 
loss-of-function mutation in the context of FcγR signalling, then a lack of regulation of immune complex signal-
ling in DCs could lead to enhanced T cell activation, augmenting immune responses to self-antigens. It would 
therefore be interesting in the future to assess the effect of PTPN22R620W on FcγR dependent immune responses 
in dendritic cells, and the impact that this has on T cell activation.
Materials and Methods
Mice. Wild type (WT) C57BL/6, Ptpn22−/− and OT-II mice were used in experiments as per protocols 
approved by the UK Home Office, and housed under specific pathogen free conditions. Ptpn22−/− mice have been 
backcrossed for more than 10 generations to the C57BL/6 strain. Brownlie, R. J. et al.49 have previously described 
their generation and phenotype. All mice used in experiments were age and gender-matched.
Bone marrow dendritic cell culture. BMDCs were produced using protocols adapted from Inaba, K. et al.50, 
and are described in detail in Clarke, F. et al.30.
CD4+ T cell isolation. CD4+ T cells were isolated from lymph nodes and spleens of WT OT-II mice using 
CD4+ T cell negative isolation kits (Miltenyi Biotech). To monitor T cell proliferation, isolated T cells were resus-
pended at 2 × 107/ml in PBS and labelled using CellTrace Violet (2 µM, CTV, Invitrogen) for 20 minutes at 37 °C, 
followed by quenching in culture media for 20 minutes at 37 °C.
Ova immune complex production. The protocol for immune complex production is based on Ellsworth J 
et al.51. For immune complexes that will bind to all FcγRs, EndoGrade ovalbumin (ova, Hyglos GmbH) and rabbit 
anti-chicken egg albumin (anti-ova, Sigma) were combined at a ratio of 1:20 (ova:anti-ova) in PBS and incubated 
at 37 °C for 1 hour. Insoluble ova immune complexes (ova ICs) were pelleted at 17,200 g at 4 °C for 30 minutes and 
resuspended in PBS or culture media. Total protein concentration was determined by BCA assay (Pierce) as per 
the manufacturer’s instructions, and added to BMDCs at 1 µM. In some experiments, ICs were added at 10 µg/ml. 
ICs were stored at 4 °C and used within 1 week of production.
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For isotype specific immune complexes, 2,4,6-Trinitrophenyl ovalbumin (TNP-ova, Santa Cruz 
Biotechnology) was combined with IgG1 specific anti-TNP (a kind gift from Dr. Michael Robson, King’s College 
London), and produced as above.
As additional controls for some experiments, BMDCs were also stimulated with 1 µM ova and 1 µM heat 
aggregated rabbit IgG (Sigma) or 1 µM ova pre-incubated with rabbit IgG (using the same procedure as making 
ova ICs, as above). Rabbit IgG was heat aggregated by being incubated at 62 °C for 20 minutes, cooled to 4 °C and 
centrifuged at 17,200 g to remove aggregates.
DC-T cell co-cultures. WT and Ptpn22−/− BMDCs were pulsed overnight with 1 µM ova or 1 µM ova ICs. 
The following day, BMDCs were harvested, washed and resuspended in DC culture media. BMDCs were seeded 
in 96 well round bottom plates and co-cultured for 1–6 days with CTV labelled WT OT-II CD4+ T cells at 1:2 
(1 × 105 BMDCs: 2 × 105 T cells). After 1 day of co-culture, cell surface expression of CD25 and CD69 (clones 
PC61 and H1.2F3 respectively, BioLegend) was assessed by flow cytometry. After 3 and 6 days of co-culture, T cell 
proliferation (via CTV dilution) and intracellular cytokine expression was determined by flow cytometry, after 
6 hours of restimulation with PMA (10 ng/ml), ionomycin (500 ng/ml) and monensin (BioLegend). Secretion of 
IL-2, IFNγ, TNFα and IL-17 was assessed in cell-free supernatants by immunoassay, as per the manufacturer’s 
instructions (BioLegend).
Immune complex stimulation of BMDCs. To assess FcγR dependent BMDC maturation, ova ICs 
were added directly to culture wells on day 6–7 of culture; ova or rabbit anti-ova alone were used as controls. 
24 hours later, BMDCs were harvested, washed, blocked with a non-fluorescent FcγRII/III antibody (clone 
2.4G2, BioLegend) and stained for cell surface expression of CD54, CD80, CD86 and MHCII I-Ab (clones 
YN1/1.7.4, 16-10A1, GL-1 and AF6-120.1 respectively, BioLegend). To identify live DCs, cells were also stained 
with anti-CD11c (clone N418, BioLegend) and a viability marker (Zombie Fixable Viability dye, BioLegend). 
Cells were washed with FACS buffer (5% FBS, 1 mM EDTA in PBS) and fixed using 1% paraformaldehyde (PFA, 
Electron Microscopy Sciences) in PBS prior to flow cytometry. Maturation marker expression was determined by 
gating on live CD11c+ singlets.
To determine FcγR induced cytokine production, BMDCs were harvested on day 7 of culture, counted and 
replated in 96 well round bottom plates at 2 × 105/well, and stimulated with ova, rabbit anti-ova, ova pre-incubated 
with rabbit IgG, or ova ICs for 3–24 hours, in the presence of polymyxin B (50 µg/ml, Sigma). Cell-free superna-
tants were removed and assessed for IL-6, TNFα, and IL-12/23p40 cytokine expression by immunoassay as per 
the manufacturer’s instructions (BioLegend).
BMDC FcγR expression. For cell surface FcγR expression, BMDCs were harvested, washed and stained 
using the following antibodies: FcγRI-APC (clone X545/7.1, BioLegend), FcγRII/III-FITC (clone 2.4G2, 
BioLegend), FcγRIIb (clone K9.361 cl5; a kind gift from Prof. Jeffrey Ravetch, Rockefeller University) followed by 
goat anti-mouse AF488 (Invitrogen) and FcγRIV (clone MB1 9E9 cl27; also a kind gift from Prof. Jeffrey Ravetch) 
followed by goat anti-hamster FITC (AbD Serotec). FcγRIII expression was determined by using anti-FcγRIIb 
followed by FcγRII/III-FITC. Cells were washed with FACS buffer and fixed using 1% PFA in PBS prior to flow 
cytometry. FcγR expression was determined by gating on live CD11c+ singlets.
Immune complex uptake, degradation and presentation assays. For immune complex uptake, 
BMDCs (2 × 105) were incubated with ova-AF488 (10 µg/ml, Invitrogen) immune complexes on ice for 45 min-
utes. Cells were washed with cold FACS buffer and incubated at 37 °C for 0–60 minutes. Further immune com-
plex uptake was prevented by returning the samples to ice and washing with cold PBS. Cells were stained using 
anti-CD11c (BioLegend), F(ab’)2 goat anti-rabbit IgG-AF647 (Invitrogen) and a viability marker (Zombie Fixable 
Viability dye, BioLegend). Cells were washed with FACS buffer and fixed using 1% PFA in PBS prior to flow 
cytometry. Cell surface ova-AF488 ICs were identified as F(ab’)2 goat anti-rabbit IgG-AF647+, as this would bind 
to rabbit anti-ova-containing ICs. BMDCs with internalised ova-AF488 ICs were identified by gating on F(ab’)2 
goat anti-rabbit IgG-AF647- live CD11c+ singlets. To identify the role of FcγRs and Src and Syk family kinases in 
immune complex uptake, WT BMDCs were pre-incubated with anti-FcγRI, II/III and IV for 15 minutes at 4 °C, 
Src inhibitor-1 (5 µM, Sigma) for 15 minutes at 37 °C, or Syk inhibitor II (5 µM, Calbiochem) for 15 minutes at 
37 °C, prior to the ova-AF488 IC uptake assay (described above).
For immune complex degradation, 3 µm polystyrene beads (Polysciences) were coated overnight with 
ova-AF594 (0.5 mg/ml, Invitrogen) at 4 °C. The following day, ova coated beads were washed and incubated for 
20 minutes on ice with rabbit anti-ova (50 μg/ml, Sigma). 1 × 105 BMDCs and 2 × 106 ova/anti-ova coated beads 
(1 DC:20 beads) were added to wells of a 96 well round bottom plate, centrifuged for 5 minutes at 750 g and 
incubated at 37 °C, 5% CO2 for 0–7 hours. To exclude non-internalised beads, BMDCs were washed and stained 
for 20 minutes on ice with F(ab’)2 goat anti-rabbit IgG-AF647 (Invitrogen). Cells were washed with FACS buffer 
and lysed for 10 minutes on ice in lysis buffer (0.5% NP-40, 50 mM Tris, 150 mM NaCl). Beads were washed with 
FACS buffer twice and transferred to FACS tubes for flow cytometry. Internalised beads were identified as F(ab’)2 
goat anti-rabbit IgG-AF647-.
For immune complex derived antigen presentation, 2 × 105 WT or Ptpn22−/− BMDCs were seeded per well of 
a 96 well round bottom plate and incubated with immune complexes containing GFP-Eα (0.3 mg/ml, a kind gift 
from Erwan Boëdec, Paris 7 University) and anti-GFP (Invitrogen) for 5 or 18 hours at 37 °C, 5% CO2. BMDCs 
were harvested, washed and stained for 30 minutes on ice with anti-CD11c (BioLegend), anti-Eα52–68-biotin 
(eBioscience) and a viability marker (Fixable Viability Dye eFluor 506, eBioscience). Cells were washed with 
FACS buffer and stained at room temperature for 10 minutes with streptavidin-APC (BioLegend) in PBS. Cells 
were washed with FACS buffer and fixed using 1% PFA in PBS prior to flow cytometry. BMDCs were identified 
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as live CD11c+ singlets. To measure cell surface MHCII expression, BMDCs in separate wells (which did not 
receive GFP-Eα:anti-GFP immune complexes) were also stained with anti-CD11c (BioLegend), anti-MHCII I-Ab 
(BioLegend) and a viability marker (Fixable Viability Dye eFluor 506, eBioscience).
DC-T cell conjugate assay. BMDCs were incubated overnight with 1 μM ova or ova ICs. The following 
day, BMDCs were harvested, washed and resuspended in PBS at 1 × 107/ml and labelled for 20 minutes at 37 °C 
using CellTrace Far Red (1 μM, CTFR, Invitrogen), followed by quenching in culture media for 20 minutes at 
37 °C. CTFR labelled BMDCs and CTV labelled WT OT-II CD4+ T cells were added to 1.5 ml tubes at 1:2 (1 × 105 
BMDCs: 2 × 105 T cells, in a total volume of 50 μl), centrifuged for 2 minutes at 25 g and incubated at 37 °C for 
0–120 minutes. Cells were fixed using 3% PFA in PBS, transferred to FACS tubes and acquired by flow cytometry 
using a medium flow rate. Conjugates were identified as CTV+ CTFR+ events. To identify the role of Src and Syk 
family kinases in conjugate formation, WT BMDCs were pre-incubated with Src inhibitor-1 (5 µM, Sigma) or Syk 
inhibitor II (5 µM, Calbiochem) for 15 minutes at 37 °C, prior to the conjugate assay (described above).
Data acquisition and analysis. Flow cytometry samples were acquired using a Fortessa II or FACSCanto 
II with FACS Diva software (all from BD). Data were analysed using Flowjo software version 10 (TreeStar). All 
graphs were plotted using Prism version 7 (GraphPad) and analysed for statistical significance using a 2-way 
ANOVA followed by Sidak’s or Tukey’s multiple comparisons test, Wilcoxon matched-pairs signed ranks test or a 
paired t-test. p < 0.05 was deemed statistically significant.
Data availability. All data generated or analysed during this study are included in the published article (and 
its Supplementary Information files).
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